Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R and Romney S: Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365-1371, 1995.
zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ and Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ and Offringa R: Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62: 472-479, 2002.
Konya J, Eklund C, af GV, Yuan F, Stuber G and Dillner J: Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. J Gen Virol 78: 2615-2620, 1997.
Liu DW, Tsao YP, Hsieh CH, Hsieh JT, Kung JT, Chiang CL, Huang SJ and Chen SL: Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth. J Virol 74: 9083-9089, 2000.
Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R and van der Burg SH: Frequent display of human papillomavirus type 16 E6-specific memory t- Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63: 636-641, 2003.
Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJ and Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154: 5934-5943, 1995.
van der Burg SH, Ressing ME, Kwappenberg KM, de Jong A, Straathof K, de Jong J, Geluk A, van Meijgaarden KE, Franken KL, Ottenhoff TH, Fleuren GJ, Kenter G, Melief CJ and Offringa R: Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes. Int J Cancer 91: 612-618, 2001.
Zehbe I, Wilander E, Delius H and Tommasino M: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58: 829-833, 1998.
Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V and Man S: Use of fluorogenic histocompatibility leukocyte antigen-A*0201/ HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte- recognizing endogenous human papillomavirus antigens. Cancer Res 60: 365-371, 2000.
Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M and Palefsky JM: Encapsulated plasmid DNA treatment for human papillomavirus 16- associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 8: 1028-1037, 2002.
Ling M, Kanayama M, Roden R and Wu T: Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers [In Process Citation]. J Biomed Sci 7: 341-356, 2000.
Frazer I: Vaccines for papillomavirus infection. Virus Res 89: 271-274, 2002.
Berry JM and Palefsky JM: A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 8: s333-s345, 2003.
Galloway DA: Papillomavirus vaccines in clinical trials. Lancet Infect Dis 3: 469-475, 2003.
Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M and Zacny VL: Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20: 7888-7898, 2001.
Tindle RW: Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev Cancer 2: 59-65, 2002.
Phelps WC, Munger K, Yee CL, Barnes JA and Howley PM: Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66: 2418-2427, 1992.
Banks L, Edmonds C and Vousden KH: Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. Oncogene 5: 1383-1389, 1990.
Jones DL, Thompson DA and Munger K: Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239: 97-107, 1997.
Jochmus I, Schafer K, Faath S, Muller M and Gissmann L: Chimeric virus-like particles Of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res 30: 269-274, 1999.
van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK and Offringa R: Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19: 3652-3660, 2001.
Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI and Mizzen LA: Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121: 216-225, 2000.
Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M and Wu TC: Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-678, 2001.
Giannouli C, Brulet JM, Gesche F, Rappaport J, Burny A, Leo O and Hallez S: Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Anticancer Res 23: 3523-3531, 2003.
Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M and Wu TC: Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. J Immunol 166: 5733-5740, 2001.
Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H and Muller M: Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 294: 47-59, 2002.
Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M and Wu TC: Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 61: 3698-3703, 2001.
Hung CF, Hsu KF, Cheng WF, Chai CY, He L, Ling M and Wu TC: Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res 61: 1080-1088, 2001.
Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ and Frazer IH: Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20: 862-869, 2001.
Hung CF, Cheng WF, He L, Ling M, Juang J, Lin CT and Wu TC: Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 63: 2393-2398, 2003.
Gerard CM, Baudson N, Kraemer K, Bruck C, Garcon N, Paterson Y, Pan ZK and Pardoll D: Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 19: 2583-2589, 2001.
Lamikanra A, Pan ZK, Isaacs SN, Wu TC and Paterson Y: Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 75: 9654-9664, 2001.
Shi W, Bu P, Liu J, Polack A, Fisher S and Qiao L: Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol 73: 7877-7881, 1999.
Smahel M, Sima P, Ludvikova V and Vonka V: Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238, 2001.
Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ and Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16- transformed cells. Eur J Immunol 23: 2242-2249, 1993.
Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26, 1996.
Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A and Leo O: Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 81: 428-437, 1999.
Aida Y and Pabst MJ: Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 132: 191-195, 1990.
De Smedt T, Pajak B, Muraille E, Lespagnard L, Heinen E, De Baetselier P, Urbain J, Leo O and Moser M: Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184: 1413-1424, 1996.
Tindle RW, Croft S, Herd K, Malcolm K, Geczy AF, Stewart T and Fernando GJ: A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin Exp Immunol 101: 265-271, 1995.
Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM and Wu TC: Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 78: 41-45, 1998.
Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K and Inglis SC: Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 14: 1485-1494, 1996.
Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS and Zwierzina H: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8: 3676-3685, 2002.
Le Buanec H, Cohen L, Paturance S, Burny A, Gallo RC and Zagury D: Therapeutic vaccine to control stromal tumor-induced immunosuppression in human uterine cervixc cancer. Cell Mol Biol (Noisy -le-grand) 49: 667-671, 2003.
Braspenning J, Manetti R, Zumbach K, Meschede W, Gissmann L and Tommasino M: A general purification protocol for E7 proteins from "high- and low-risk" human papillomavirus types expressed in the yeast Schizosaccharomyces pombe. Protein Expr Purif 10: 192-201, 1997.
Polevoda B, Norbeck J, Takakura H, Blomberg A and Sherman F: Identification and specificities of N-terminal acetyltransferases from Saccharomyces cerevisiae. EMBO J 18: 6155-6168, 1999.
Reinstein E, Scheffner M, Oren M, Ciechanover A and Schwartz A: Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19: 5944-5950, 2000.
Coulie PG: Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? Mol Med Today 3: 261-268, 1997.
Stittelaar KJ, Boes J, Kersten GF, Spiekstra A, Mulder PG, de Vries P, Roholl PJ, Dalsgaard K, van den DG, van Alphen L and Osterhaus AD: In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components. Vaccine 18: 2482-2493, 2000.
Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR and Kast WM: Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22: 520-527, 2004.
Luxton JC, Rowe AJ, Cridland JC, Coletart T, Wilson P and Shepherd PS: Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J Gen Virol 77(Pt 7): 1585-1593, 1996.
Tsukui T, Hildesheim A, Schiffman MH, Lucci J, III, Contois D, Lawler P, Rush BB, Lorincz AT, Corrigan A, Burk RD, Qu W, Marshall MA, Mann D, Carrington M, Clerici M, Shearer GM, Carbone DP, Scott DR, Houghten RA and Berzofsky JA: Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res 56: 3967-3974, 1996.
Kast WM, Brandt RM, Drijfhout JW and Melief CJ: Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 14: 115-120, 1993.
Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V and Weber J: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6: 3406-3416, 2000.
